Acorda's $525m Civitas buy: Sign of Parkinson's deal surge?
This article was originally published in Scrip
Civitas Therapeutics has a lot to offer its buyer Acorda Therapeutics, including global diversification and an inhaled drug platform technology. The private company's $525m acquisition adds to a growing list of recent transactions in the Parkinson's disease field.
You may also be interested in...
Citing recent deals, hedge fund Scopia encouraged Acorda's board on Aug. 7 to pursue a sale, but the company believes its new strategy focused on Parkinson's disease is best for shareholders.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.